{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:03:20Z","timestamp":1791331400741,"version":"4.3.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Metastatic castration resistant prostate cancer (mCRPC) is still the lethal stage for the whole spectrum of prostate cancer disease. Even though different treatment options have been introduced in the last decade with a significant survival improvement for this population, a lack of more reliable prognostic and predictive markers is still one of the main clinical challenges in management of mCRPC. The aim of this study was to investigate the correlation between Natural Killer cell activity (NKA) and both treatment effect and outcomes in patients with mCRPC treated with enzalutamide. A total of 87 patients with mCRPC treated with enzalutamide as the first line treatment were enrolled. NKA was estimated at baseline and prior to each treatment cycle. Endpoints included both treatment effect with biochemical response (BR), biochemical progression (BP) and radiological progression (RP), as well as outcome data with overall survival (OS), radiologic progression free survival (rPFS), and time to next treatment (TTT). At the time of BR, interferon-gamma (IFN\u03b3) decreased significantly compared to levels detected at baseline (z-score\u2009=\u20092.33, p\u2009=\u20090.019). Regarding outcome data, the whole cohort was divided into four groups according to the change of IFN\u03b3 level during the first 3 cycles of enzalutamide treatment. In group 1 (n\u2009=\u200942) the IFN\u03b3 level remained within a normal range (\u2265\u2009250\u00a0pg\/mL),while in group 2 (n\u2009=\u20097) it increased from an abnormal (&lt;\u2009250\u00a0pg\/mL) to a normal level. In group 3 (n\u2009=\u200913) it dropped to an abnormal level, and it remained at an abnormal level during treatment in group 4 (n\u2009=\u200917). Patients in group 2 showed the worst prognosis with shorter both rPFS and TTT (HR 4.30, p\u2009=\u20090.037; and HR 6.82, p\u2009=\u20090.011, respectively). In this study inverse correlations between NKA and both treatment response and outcomes was observed in mCRPC patients receiving enzalutamide, suggesting an unfavourable role of NK cells in the late stage of PCa.<\/jats:p>","DOI":"10.1038\/s41598-023-43937-7","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T18:02:27Z","timestamp":1696960947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide"],"prefix":"10.1038","volume":"13","author":[{"given":"A. H.","family":"Zedan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nederby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. M.","family":"Volmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. V.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. E.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. F.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"43937_CR1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/OP.21.00206","volume":"18","author":"N Sayegh","year":"2022","unstructured":"Sayegh, N., Swami, U. & Agarwal, N. Recent advances in the management of metastatic prostate cancer. JCO Oncol. Pract. 18, 45\u201355 (2022).","journal-title":"JCO Oncol. Pract."},{"key":"43937_CR2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2012.12.029","volume":"64","author":"A Omlin","year":"2013","unstructured":"Omlin, A. et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur. Urol. 64, 300\u2013306 (2013).","journal-title":"Eur. Urol."},{"key":"43937_CR3","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","volume":"375","author":"HI Scher","year":"2010","unstructured":"Scher, H. I. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1\u20132 study. Lancet 375, 1437\u20131446 (2010).","journal-title":"Lancet"},{"key":"43937_CR4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121\u2013131 (2019).","journal-title":"N. Engl. J. Med."},{"key":"43937_CR5","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong, A. J. et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37, 2974\u20132986 (2019).","journal-title":"J. Clin. Oncol."},{"key":"43937_CR6","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187\u20131197 (2012).","journal-title":"N. Engl. J. Med."},{"key":"43937_CR7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","volume":"71","author":"TM Beer","year":"2017","unstructured":"Beer, T. M. et al. Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: Extended analysis of the phase 3 PREVAIL study. Eur. Urol. 71, 151\u2013154 (2017).","journal-title":"Eur. Urol."},{"key":"43937_CR8","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg, C. N. et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 382, 2197\u20132206 (2020).","journal-title":"N. Engl. J. Med."},{"key":"43937_CR9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00345-018-2574-2","volume":"38","author":"M Pinart","year":"2020","unstructured":"Pinart, M. et al. Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: A systematic review. World J. Urol. 38, 613\u2013635 (2020).","journal-title":"World J. Urol."},{"key":"43937_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"X Gu","year":"2016","unstructured":"Gu, X. et al. Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: Evidence from 16,266 patients. Sci. Rep. 6, 1\u20137 (2016).","journal-title":"Sci. Rep."},{"key":"43937_CR11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ijc.2910160204","volume":"16","author":"RB Herberman","year":"1975","unstructured":"Herberman, R. B., Nunn, M. E. & Lavrin, D. H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int. J. Cancer 16, 216\u2013229 (1975).","journal-title":"Int. J. Cancer"},{"key":"43937_CR12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/eji.1830050208","volume":"5","author":"R Kiessling","year":"1975","unstructured":"Kiessling, R., Klein, E. & Wigzell, H. Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. 5, 112\u2013117 (1975).","journal-title":"Eur. J. Immunol."},{"key":"43937_CR13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41577-019-0139-2","volume":"19","author":"KL O\u2019Brien","year":"2019","unstructured":"O\u2019Brien, K. L. & Finlay, D. K. Immunometabolism and natural killer cell responses. Nat. Rev. Immunol. 19, 282\u2013290 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"43937_CR14","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1182\/blood.V76.12.2421.2421","volume":"76","author":"MJ Robertson","year":"1990","unstructured":"Robertson, M. J. & Ritz, J. Biology and clinical relevance of human natural killer cells. Blood 76, 2421\u20132438 (1990).","journal-title":"Blood"},{"key":"43937_CR15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","volume":"22","author":"MA Cooper","year":"2001","unstructured":"Cooper, M. A., Fehniger, T. A. & Caligiuri, M. A. The biology of human natural killer-cell subsets. Trends Immunol. 22, 633\u2013640. https:\/\/doi.org\/10.1016\/S1471-4906(01)02060-9 (2001).","journal-title":"Trends Immunol."},{"key":"43937_CR16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ucl.2020.07.002","volume":"47","author":"N Bhardwaj","year":"2020","unstructured":"Bhardwaj, N., Farkas, A. M., Gul, Z. & Sfakianos, J. P. Harnessing natural killer cell function for genitourinary cancers. Urol. Clin. North Am. 47, 433\u2013442 (2020).","journal-title":"Urol. Clin. North Am."},{"key":"43937_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","volume":"9","author":"F Castro","year":"2018","unstructured":"Castro, F., Cardoso, A. P., Gon\u00e7alves, R. M., Serre, K. & Oliveira, M. J. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front. Immunol. 9, 847. https:\/\/doi.org\/10.3389\/fimmu.2018.00847 (2018).","journal-title":"Front. Immunol."},{"key":"43937_CR18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","volume":"16","author":"BS Parker","year":"2016","unstructured":"Parker, B. S., Rautela, J. & Hertzog, P. J. Antitumour actions of interferons: Implications for cancer therapy. Nat. Rev. Cancer 16, 131\u2013144 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"43937_CR19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","volume":"76","author":"TBL Lam","year":"2019","unstructured":"Lam, T. B. L. et al. EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an International Collaborative Study (DETECTIVE Study). Eur. Urol. 76, 790\u2013813. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.020 (2019).","journal-title":"Eur. Urol."},{"key":"43937_CR20","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher, H. I. et al. Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3. J. Clin. Oncol. 34, 1402\u20131418 (2016).","journal-title":"J. Clin. Oncol."},{"key":"43937_CR21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"43937_CR22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jim.2018.04.002","volume":"458","author":"L Nederby","year":"2018","unstructured":"Nederby, L., Jakobsen, A., Hokland, M. & Hansen, T. F. Quantification of NK cell activity using whole blood: Methodological aspects of a new test. J. Immunol. Methods 458, 21\u201325 (2018).","journal-title":"J. Immunol. Methods"},{"key":"43937_CR23","first-page":"8708","volume":"24","author":"J Barkin","year":"2017","unstructured":"Barkin, J., Rodriguez-Suarez, R. & Betito, K. Association between natural killer cell activity and prostate cancer: A pilot study. Can. J. Urol. 24, 8708\u20138713 (2017).","journal-title":"Can. J. Urol."},{"key":"43937_CR24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1590\/s1677-5538.ibju.2019.0268","volume":"46","author":"BS Tae","year":"2020","unstructured":"Tae, B. S. et al. Can natural killer cell activity help screen patients requiring a biopsy for the diagnosis of prostate cancer?. Int. Braz J Urol 46, 244\u2013252 (2020).","journal-title":"Int. Braz J Urol"},{"key":"43937_CR25","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3389\/fimmu.2017.01194","volume":"8","author":"A Zingoni","year":"2017","unstructured":"Zingoni, A. et al. Natural killer cell response to chemotherapy-stressed cancer cells: Role in tumor immunosurveillance. Front. Immunol. 8, 1194 (2017).","journal-title":"Front. Immunol."},{"key":"43937_CR26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0002-9610(94)90070-1","volume":"167","author":"TA Colacchio","year":"1994","unstructured":"Colacchio, T. A., Yeager, M. P. & Hildebrandt, L. W. Perioperative immunomodulation in cancer surgery. Am. J. Surg. 167, 174\u2013179 (1994).","journal-title":"Am. J. Surg."},{"key":"43937_CR27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1099800409343204","volume":"11","author":"SJ Yermal","year":"2010","unstructured":"Yermal, S. J., Witek-Janusek, L., Peterson, J. & Mathews, H. L. Perioperative pain, psychological distress, and immune function in men undergoing prostatectomy for cancer of the prostate. Biol. Res. Nurs. 11, 351\u2013362 (2010).","journal-title":"Biol. Res. Nurs."},{"key":"43937_CR28","first-page":"359","volume":"9","author":"H Yamazaki","year":"2002","unstructured":"Yamazaki, H. et al. Changes in natural killer cell activity by external radiotherapy and\/or brachytherapy. Oncol. Rep. 9, 359\u2013363 (2002).","journal-title":"Oncol. Rep."},{"key":"43937_CR29","doi-asserted-by":"crossref","first-page":"1496881","DOI":"10.1080\/2162402X.2018.1496881","volume":"7","author":"F Eckert","year":"2018","unstructured":"Eckert, F. et al. Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. Oncoimmunology 7, 1496881 (2018).","journal-title":"Oncoimmunology"},{"key":"43937_CR30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/pros.2990210204","volume":"21","author":"M Ka\u0161Ctelan","year":"1992","unstructured":"Ka\u0161Ctelan, M., Tarle, M. & Kralji\u0107, I. NK cell activity in treated prostate cancer patients as a probe for circulating tumor cells: Hormone regulatory effects in vivo. Prostate 21, 111\u2013120 (1992).","journal-title":"Prostate"},{"key":"43937_CR31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jim.2009.06.004","volume":"348","author":"PO Gannon","year":"2009","unstructured":"Gannon, P. O. et al. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J. Immunol. Methods 348, 9\u201317 (2009).","journal-title":"J. Immunol. Methods"},{"key":"43937_CR32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canlet.2017.03.035","volume":"398","author":"SJ Lin","year":"2017","unstructured":"Lin, S. J. et al. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). Cancer Lett. 398, 62\u201369 (2017).","journal-title":"Cancer Lett."},{"key":"43937_CR33","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.3390\/cancers13215574","volume":"13","author":"L Fan","year":"2021","unstructured":"Fan, L. et al. Type i interferon promotes antitumor t cell response in crpc by regulating mdsc. Cancers 13, 5574 (2021).","journal-title":"Cancers"},{"key":"43937_CR34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","volume":"24","author":"J Stultz","year":"2021","unstructured":"Stultz, J. & Fong, L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostat. Dis. 24, 697\u2013717 (2021).","journal-title":"Prostate Cancer Prostat. Dis."},{"key":"43937_CR35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.10538,105-105","author":"SU Gandhy","year":"2020","unstructured":"Gandhy, S. U. et al. PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2020.38.6_suppl.10538,105-105 (2020).","journal-title":"J. Clin. Oncol."},{"key":"43937_CR36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/ctm2.505","volume":"11","author":"H Haque Chowdhury","year":"2021","unstructured":"Haque Chowdhury, H. et al. Survival of castration-resistant prostate cancer patients treated with dendritic-tumor cell hybridomas is negatively correlated with changes in peripheral blood CD56 bright CD16 - natural killer cells. Clin. Transl. Med. 11, 505 (2021).","journal-title":"Clin. Transl. Med."},{"key":"43937_CR37","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s40425-019-0787-6","volume":"7","author":"H Westdorp","year":"2019","unstructured":"Westdorp, H. et al. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant. J. Immunother. Cancer 7, 302 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"43937_CR38","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1038\/s41598-019-40933-8","volume":"9","author":"K de Jonge","year":"2019","unstructured":"de Jonge, K. et al. Circulating CD56 bright NK cells inversely correlate with survival of melanoma patients. Sci. Rep. 9, 4487 (2019).","journal-title":"Sci. Rep."},{"key":"43937_CR39","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2020009871","volume":"138","author":"C Duault","year":"2021","unstructured":"Duault, C. et al. Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. Blood 138, 1465\u20131480 (2021).","journal-title":"Blood"},{"key":"43937_CR40","first-page":"1","volume":"8","author":"KC Koo","year":"2013","unstructured":"Koo, K. C. et al. Reduction of the CD16-CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer. PLoS ONE 8, 1\u20138 (2013).","journal-title":"PLoS ONE"},{"key":"43937_CR41","doi-asserted-by":"crossref","first-page":"14360","DOI":"10.18632\/oncotarget.3965","volume":"6","author":"C Pasero","year":"2015","unstructured":"Pasero, C. et al. Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. Oncotarget 6, 14360\u201314373 (2015).","journal-title":"Oncotarget"},{"key":"43937_CR42","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.tranon.2019.04.002","volume":"12","author":"TF Hansen","year":"2019","unstructured":"Hansen, T. F. et al. Correlation between natural killer cell activity and treatment effect in patients with disseminated cancer. Transl. Oncol. 12, 968\u2013972 (2019).","journal-title":"Transl. Oncol."},{"key":"43937_CR43","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/cancers12040958","volume":"12","author":"I Corbeau","year":"2020","unstructured":"Corbeau, I., Jacot, W. & Guiu, S. Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: A systematic review. Cancers 12, 958 (2020).","journal-title":"Cancers"},{"key":"43937_CR44","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.yexmp.2014.04.001","volume":"96","author":"MF Santos","year":"2014","unstructured":"Santos, M. F. et al. Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells. Exp. Mol. Pathol. 96, 367\u2013374 (2014).","journal-title":"Exp. Mol. Pathol."},{"key":"43937_CR45","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1113\/EP088627","volume":"105","author":"ED Hanson","year":"2020","unstructured":"Hanson, E. D. et al. Natural killer cell mobilization and egress following acute exercise in men with prostate cancer. Exp. Physiol. 105, 1524\u20131539 (2020).","journal-title":"Exp. Physiol."},{"key":"43937_CR46","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2019.101578","volume":"62","author":"AC Vidal","year":"2019","unstructured":"Vidal, A. C. et al. Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy. Cancer Epidemiol. 62, 101578 (2019).","journal-title":"Cancer Epidemiol."},{"key":"43937_CR47","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/142101","author":"J Amankulov","year":"2021","unstructured":"Amankulov, J. et al. Natural killer cell activity level in colorectal cancer screening in an average risk population. Arch. Med. Sci. https:\/\/doi.org\/10.5114\/aoms\/142101 (2021).","journal-title":"Arch. Med. Sci."},{"key":"43937_CR48","doi-asserted-by":"crossref","first-page":"11089","DOI":"10.1177\/03000605221108924","volume":"50","author":"M Borg","year":"2022","unstructured":"Borg, M. et al. Natural killer cell activity as a biomarker for the diagnosis of lung cancer in high-risk patients. J. Int. Med. Res. 50, 11089 (2022).","journal-title":"J. Int. Med. Res."},{"key":"43937_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc1782","volume":"6","author":"KE De Visser","year":"2006","unstructured":"De Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24\u201337. https:\/\/doi.org\/10.1038\/nrc1782 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"43937_CR50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.11648\/j.ajcem.20190701.14","volume":"7","author":"U-G Lo","year":"2019","unstructured":"Lo, U.-G. et al. Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion. Am. J. Clin. Exp. Urol. 7, 31\u201345 (2019).","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"43937_CR51","first-page":"1098","volume":"79","author":"UG Lo","year":"2019","unstructured":"Lo, U. G. et al. IFNG-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via miRNA processing. Cancer Res. 79, 1098\u20131112 (2019).","journal-title":"Cancer Res."},{"key":"43937_CR52","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1158\/0008-5472.CAN-19-0596","volume":"79","author":"M Song","year":"2019","unstructured":"Song, M. et al. Low-dose IFNg induces tumor cell stemness in tumor microenvironment of non\u2013small cell lung cancer. Cancer Res. 79, 3737\u20133748 (2019).","journal-title":"Cancer Res."},{"key":"43937_CR53","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/pros.23988","volume":"80","author":"M Tang","year":"2020","unstructured":"Tang, M. et al. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals. Prostate 80, 742\u2013752 (2020).","journal-title":"Prostate"},{"key":"43937_CR54","first-page":"6222324","volume":"2023","author":"T Liu","year":"2023","unstructured":"Liu, T. & Zhuo, L. The role of C-reactive protein in the prognosis of prostate cancer: A meta-analysis. J. Environ. Public Health 2023, 6222324 (2023).","journal-title":"J. Environ. Public Health"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43937-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43937-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43937-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T13:14:59Z","timestamp":1700313299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43937-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43937"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-43937-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TFH has received research funding from ATGen Co. Ltd. The company had no influence on the study design, analyses, data interpretation, manuscript preparation, or submission process.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17144"}}